Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2024 | 08/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.19% | 28.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.19% | 28.65% | |||
| Cost of Revenue | 22.59% | 31.42% | |||
| Gross Profit | -17.95% | 27.12% | |||
| SG&A Expenses | 7.22% | 0.46% | |||
| Depreciation & Amortization | -4.63% | -39.54% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.06% | 0.99% | |||
| Operating Income | -18.03% | 10.58% | |||
| Income Before Tax | -23.52% | 12.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.52% | 12.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.52% | 12.94% | |||
| EBIT | -18.03% | 10.58% | |||
| EBITDA | -19.44% | 10.26% | |||
| EPS Basic | -23.08% | 14.47% | |||
| Normalized Basic EPS | -21.95% | 12.77% | |||
| EPS Diluted | -23.08% | 14.47% | |||
| Normalized Diluted EPS | -21.95% | 12.77% | |||
| Average Basic Shares Outstanding | 0.86% | 1.11% | |||
| Average Diluted Shares Outstanding | 0.86% | 1.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
